Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface

Nature

Volumn 515, Issue 7525, 2014, Pages 138-142

  Huang, Jinghe ^a   Kang, Byong H ^a   Pancera, Marie ^a   Lee, Jeong Hyun ^b   Tong, Tommy ^c   Feng, Yu ^b   Imamichi, Hiromi ^a   Georgiev, Ivelin S ^a   Chuang, Gwo Yu ^a   Druz, Aliaksandr ^a   Doria Rose, Nicole A ^a   Laub, Leo ^a   Sliepen, Kwinten ^d   Van Gils, Marit J ^d   De La Peña, Alba Torrents ^d   Derking, Ronald ^d   Klasse, Per Johan ^e   Migueles, Stephen A ^a   Bailer, Robert T ^a   Alam, Munir ^f   Pugach, Pavel ^e   Haynes, Barton F ^f   Wyatt, Richard T ^b   Sanders, Rogier W ^d,e   Binley, James M ^c   Ward, Andrew B ^b   Mascola, John R ^a   Kwong, Peter D ^a   Connors, Mark ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c San Diego Biomedical Research Institute   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

ANTIBODY; CONCENTRATION (COMPOSITION); HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; INHIBITION; NEUTRALIZATION; PROTEIN; RECONSTRUCTION; SERUM; VACCINE; VULNERABILITY;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLADISTICS; CONFORMATIONAL TRANSITION; CRYSTALLOGRAPHY; DISULFIDE BOND; ELECTRON MICROSCOPY; GLYCOSYLATION; HEAVY CHAIN; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; LIGHT CHAIN; MEMORY CELL; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; SOMATIC MUTATION; SURFACE PLASMON RESONANCE; VIRION; VIRUS LIKE AGENT; VIRUS SPIKE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL LINE; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; EPITOPE MAPPING; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; ULTRASTRUCTURE; VIROLOGY; VIRUS ENTRY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGENS, CD4; CELL LINE; CELL MEMBRANE; CONSERVED SEQUENCE; EPITOPE MAPPING; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; RECEPTORS, CCR5; VIRUS INTERNALIZATION;

EID: 84921607768     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13601     Document Type: Article

References (47)

1. Kwong, P. D. & Mascola, J. R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425 (2012).
2. Doria-Rose, N. A. et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631-1636 (2010).
3. Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757-769 (2009).
4. Walker, L. M. et al. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog. 6, e1001028 (2010).
5. Simek, M. D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348 (2009).
6. Gray, E. S. et al. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83, 8925-8937 (2009).
7. Walker, L. M. et al. Broad and potent neutralizing antibodies froman African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
8. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
9. Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nature Protocols 8, 1907-1915 (2013).
10. Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008).
11. Scheid, J. F. et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458, 636-640 (2009).
12. Bonsignori, M. et al. Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J. Virol. 86, 4688-4692 (2012).
13. Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
14. Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024-1027 (1994).
15. Muster, T. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647 (1993).
16. Scharf, L. et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7, 785-795 (2014).
17. Falkowska, E. et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657-668 (2014).
18. Blattner, C. et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 40, 669-680 (2014).
19. Zhang, M. Y. et al. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoSONE 7, e44241 (2012).
20. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
21. Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633-1637 (2011).
22. Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126-138 (2013).
23. Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906-1908 (2005).
24. Mouquet, H. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591-595 (2010).
25. Doores, K. J. & Burton, D. R. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84, 10510-10521 (2010).
26. Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
27. Ringe, R. P. et al. Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc. Natl Acad. Sci. USA 110, 18256-18261 (2013).
28. Georgiev, I. S. et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 340, 751-756 (2013).
29. Pancera, M. & Wyatt, R. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage. Virology 332, 145-156 (2005).
30. Crooks, E. T. et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies 14, 101-113 (2005).
31. Tong, T., Crooks, E. T., Osawa, K. & Binley, J. M. HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes. J. Virol. 86, 3574-3587 (2012).
32. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
33. Chakrabarti, B. K. et al. Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity. J. Virol. 85, 8217-8226 (2011).
34. Binley, J. M. et al. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77, 5678-5684 (2003).
35. Chuang, G. Y. et al. Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains. J. Virol. 87, 10047-10058 (2013).
36. Pancera, M. et al. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J. Virol. 79, 9954-9969 (2005).
37. Yasmeen, A. et al. Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. Retrovirology (in the press) (2014).
38. McLellan, J. S. et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336-343 (2011).
39. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr. A 276, 307-326 (1997).
40. McCoy, A. J. et al. Phaser crystallographic software. J.Appl. Crystallogr. 40, 658-674 (2007).
41. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011).
42. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. 60, 2126-2132 (2004).
43. Davis, I. W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).
44. Kong, L. et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nature Struct. Mol. Biol. 20, 796-803 (2013).
45. Thornburg, N. J. et al. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses. J. Clin. Invest. 123, 4405-4409 (2013).
46. Julien, J. P. et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342, 1477-1483 (2013).
47. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G. & Subramaniam, S. Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113 (2008).